Zobrazeno 1 - 10
of 113
pro vyhledávání: '"Jennifer Arrondeau"'
Autor:
Lucia Parlati, Mehdi Sakka, Aurelia Retbi, Samir Bouam, Lamia Hassani, Jean-François Meritet, Pierre Rufat, Dominique Bonnefont-Rousselot, Rui Batista, Benoit Terris, Agnès Bellanger, Dominique Thabut, Aurore Vozy, Jean-Philippe Spano, Romain Coriat, François Goldwasser, Selim Aractingi, Philippe Sogni, Stanislas Pol, Vincent Mallet, Jérôme Alexandre, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Sixtine De Percin, Nora Kramkimel, Olivier Huillard, Jeanne Chapron, Benedicte Deau-Fischer, Marie-Laure Brandely-Piat, Diane Damotte, Audrey Lupo, Marco Alifano, Marion Corouge, Clémence Hollande, Hélène Fontaine, Lorianne Lair Mehiri, Anaïs Vallet Pichard, Patrick Tilleul
Publikováno v:
JHEP Reports, Vol 5, Iss 12, Pp 100880- (2023)
Background & Aims: There is concern about the burden of liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). Methods: In a retrospective cohort study, we evaluated the likelihood of grade 3/4 liver injury, of grade 3/
Externí odkaz:
https://doaj.org/article/788878b251bf4c95a2f7143042e64143
Autor:
Antonin Ginguay, Nora Kramkimel, Solène Lecolant, François Goldwasser, Maxime Battistella, Jennifer Arrondeau
Publikováno v:
Case Reports in Oncology, Vol 15, Iss 3, Pp 1114-1119 (2022)
Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant skin adnexal tumor. Recurrences are most often localized, and long-term follow-up after complete surgery consists essentially of self-examination of skin. We report one case of metastati
Externí odkaz:
https://doaj.org/article/63fe58e898214f50a0908222caf98d0c
Autor:
Michelle Rosenzwajg, Joe-Elie Salem, Yves Allenbach, Stephane Ederhy, Noël Zahr, Jean-Paul Mira, Lee S Nguyen, Javid Moslehi, Marie Bretagne, Jennifer Arrondeau, Baptiste Abbar, Bruno Pinna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/b52d42ec7efd48709f7ba5fce570309a
Autor:
Kinan El Husseini, Hélène Lafoeste, Audrey Mansuet-Lupo, Jennifer Arrondeau, Clémentine Villeminey, Souhail Bennani, Marie-Pierre Revel, Marie Wislez
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 4, Iss , Pp 100101- (2021)
Immune checkpoint inhibitors have emerged as a cornerstone of management in non-small-cell lung cancer (NSCLC). They are responsible for a wide spectrum of immune-related adverse effects, which greatly differ from the adverse events of standard chemo
Externí odkaz:
https://doaj.org/article/bc696307854b4901b2bd85f1f3a2e915
Autor:
Pascaline Boudou-Rouquette, Jennifer Arrondeau, Claire Gervais, Jean-Philippe Durand, Elizabeth Fabre, Sixtine De Percin, Clémentine Vaquin Villeminey, Anne-Catherine Piketty, Nathalie Rassy, Guillaume Ulmann, Diane Damotte, Audrey Mansuet-Lupo, Frédérique Giraud, Marco Alifano, Marie Wislez, Jérôme Alexandre, Anne Jouinot, François Goldwasser
Publikováno v:
EBioMedicine, Vol 73, Iss , Pp 103630- (2021)
Background: Immune checkpoint inhibitors (ICI) are dramatically active in a minority of non-small cell lung cancer (NSCLC) patients. We studied here the relationship between patients's metabolism and outcome under ICI. Methods: Metastatic NSCLC patie
Externí odkaz:
https://doaj.org/article/c752ad522f9e41baab6f8929446462cf
Autor:
Diane Damotte, Sarah Warren, Jennifer Arrondeau, Pascaline Boudou-Rouquette, Audrey Mansuet-Lupo, Jérôme Biton, Hanane Ouakrim, Marco Alifano, Claire Gervais, Audrey Bellesoeur, Nora Kramkimel, Camille Tlemsani, Barbara Burroni, Angéline Duche, Franck Letourneur, Han Si, Rebecca Halpin, Todd Creasy, Ronald Herbst, Xing Ren, Pascale Morel, Alessandra Cesano, François Goldwasser, Karen Leroy
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-10 (2019)
Abstract Background The 18-gene tumor inflammation signature (TIS) is a clinical research assay that enriches for clinical benefit to immune checkpoint blockade. We evaluated its ability to predict clinical benefit of immunotherapy in cancer patients
Externí odkaz:
https://doaj.org/article/b75c5fd83d2d4639a48bed140c36dd2f
Autor:
Thomas Rodier, Alicja Puszkiel, Evelina Cardoso, David Balakirouchenane, Céline Narjoz, Jennifer Arrondeau, Vincent Fallet, Nihel Khoudour, Monia Guidi, Michel Vidal, Xavier Declèves, Chantal Csajka, Jérôme Alexandre, Jacques Cadranel, Elizabeth Fabre, Marie Wislez, François Goldwasser, Benoit Blanchet
Publikováno v:
Pharmaceutics, Vol 14, Iss 9, p 1844 (2022)
High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in plasma exposure. The aim of this study was
Externí odkaz:
https://doaj.org/article/3366d53b548347408d3e034bc944fe1d
Autor:
Johanna Noel, Anne Jouinot, Jérôme Alexandre, Guillaume Ulmann, Marie Bretagne, Zahra Castel-Ajgal, Sixtine De Percin, Clémentine Vaquin-Villeminey, Marie-Pierre Revel, Michael Peyromaure, Pascaline Boudou-Rouquette, Jennifer Arrondeau, Ithar Gataa, Jean-Philippe Durand, François Goldwasser, Olivier Huillard
Publikováno v:
Cancers, Vol 14, Iss 13, p 3214 (2022)
Background: Nivolumab improved patients’ survival in metastatic renal cell carcinoma (mRCC). We aimed to evaluate resting energy expenditure (REE) (i.e., patients’ basal metabolism) to predict efficacy. Methods: We conducted a monocentric, observ
Externí odkaz:
https://doaj.org/article/f33d2c470e3342f69e9af8dd32e78d54
Autor:
Renaud Descourt, Maurice Pérol, Gaëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Jacques Cadranel, Alexis Benjamin Cortot, Florian Guisier, Loïck Galland, Pascal Do, Roland Schott, Éric Dansin, Jennifer Arrondeau, Jean-Bernard Auliac, Margaux Geier, Christos Chouaïd
Publikováno v:
Cancers, Vol 14, Iss 7, p 1751 (2022)
Brigatinib is a next-generation ALK inhibitor (ALKi) that shows efficacy in ALK inhibitor naïve and post-crizotinib ALK+ advanced NSCLCs (aNSCLCs). The efficacy of brigatinib was retrospectively assessed in patients with aNSCLCs included in the brig
Externí odkaz:
https://doaj.org/article/ba90791955d34a7bbddfe74e2136a8ec
Autor:
David Balakirouchenane, Sarah Guégan, Chantal Csajka, Anne Jouinot, Valentine Heidelberger, Alicja Puszkiel, Ouidad Zehou, Nihel Khoudour, Perrine Courlet, Nora Kramkimel, Coralie Lheure, Nathalie Franck, Olivier Huillard, Jennifer Arrondeau, Michel Vidal, Francois Goldwasser, Eve Maubec, Nicolas Dupin, Selim Aractingi, Monia Guidi, Benoit Blanchet
Publikováno v:
Cancers, Vol 12, Iss 4, p 931 (2020)
Patients treated with dabrafenib/trametinib (DAB/TRA) exhibit a large interindividual variability in clinical outcomes. The aims of this study were to characterize the pharmacokinetics of DAB, hydroxy-dabrafenib (OHD), and TRA in BRAF-mutated patient
Externí odkaz:
https://doaj.org/article/a08b6b4f2c8f41e8b63e6ca0706be129